Tesamorelin is primarily available as a prescription medicine for approved medical uses, whilst versions referred to as „research peptides” are also sold online by peptide suppliers operating in the research market, where levels of quality control and regulatory oversight can vary significantly. In the United States, tesamorelin has been approved by the FDA under the trade name Egrifta SV for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, which means that legal pharmaceutical tesamorelin usually requires a prescription and medical supervision. Outside the official medical channel, tesamorelin is also offered by suppliers of research peptides, including Semax Polska, where products are usually labelled for research purposes only and are not intended for human use.
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) which stimulates endogenous growth hormone (GH) and insulin-like growth factor-1 (IGF-1) production. Due to its direct effect on hormonal and endocrinological pathways, in most countries it is regulated as a prescription therapeutic peptide rather than a dietary supplement. Legal medical access typically involves a doctor's consultation, laboratory tests, and regular monitoring of IGF-1 levels, glucose metabolism, and other metabolic parameters during therapy.
In the United States, tesamorelin gained FDA approval in 2010 for the treatment of HIV-associated lipodystrophy, following numerous Phase III clinical trials that demonstrated significant reductions in visceral adipose tissue and improvements in metabolic markers. Pharmaceutical-grade tesamorelin is manufactured to stringent quality standards, including tests for purity, sterility, stability, and dose consistency. The medication is typically distributed through licensed specialty pharmacies and prescribed by physicians specialising in endocrinology, metabolic medicine, or HIV care.
Outside of the prescription system, tesamorelin is often sold online as a „research peptide”. These products are popular in circles related to biohacking, body composition improvement, anti-aging, regeneration, and performance optimisation. However, it should be remembered that research peptides can vary significantly in terms of purity, active substance concentration, sterility, storage conditions, and production standards, as many are not subject to the same regulations as approved pharmaceutical drugs. Independent analyses of the peptide market have shown instances of contamination, mislabelling, under-dosing, or composition discrepancies in some products available online. For this reason, laboratories and individuals involved in research often choose suppliers who offer batch documentation, laboratory analyses, and Certificates of Analysis (CoAs).
In Europe, suppliers of research-grade peptides, such as Semax Polska, offer tesamorelin and other peptides exclusively for laboratory and scientific purposes. „Research use only” peptides are typically intended for analytical applications, in vitro studies or preclinical research, rather than for approved medical treatment or consumption. Companies operating in this market often provide HPLC data on purity, mass spectrometry confirmation, batch identification and recommendations for the storage of research material.
The legal status of tesamorelin varies between countries. In the US, it is classified as a prescription-only medicine and cannot be legally sold as a dietary supplement. In many European countries, the UK, Canada, and Australia, tesamorelin is also regulated as a medicine or a restricted therapeutic peptide. Importing prescription peptides without the correct authorisations may breach customs, pharmaceutical, or medical regulations depending on local law. Some countries also regulate peptides under anti-doping or performance-enhancing substance legislation.
Medical supervision remains an important consideration. Tesamorelin affects the GH-IGF-1 axis and may increase the risk of adverse events associated with water retention, oedema, joint pain, glucose intolerance, elevated IGF-1 levels, or metabolic disturbances in susceptible individuals. Clinical studies have generally shown tesamorelin to be well tolerated; however, regular monitoring of IGF-1 levels, glucose metabolism, and endocrinological parameters is usually recommended during therapy. Individuals with active malignancies, uncontrolled hormonal disorders, or certain pituitary conditions may not be suitable candidates for treatment.
From a scientific perspective, tesamorelin has extensive clinical documentation regarding the reduction of visceral fat, improvement of fatty liver, body composition, and metabolic health. However, the use of tesamorelin in bodybuilding, anti-aging, or performance enhancement outside of its approved indications remains an off-label or experimental application in many countries. This distinction is important because medical supervision, legal protection, and regulated pharmaceutical standards primarily apply to approved medical uses, not to applications related to physique or performance enhancement.
Generally speaking, tesamorelin may be legally available via prescription in countries where it has been approved, while a parallel market for research peptides offering tesamorelin solely for laboratory and scientific purposes also exists. Understanding the difference between pharmaceutical prescription tesamorelin and „research use only” peptides is important from legal, medical, safety, and quality control perspectives.
Disclaimer
This content is for educational and informational purposes only and does not constitute medical, diagnostic or legal advice. Tesamorelin is a prescription-only medicine in many countries and should only be used under the supervision of a qualified healthcare professional with appropriate laboratory monitoring. Research peptides offered by suppliers such as Semax Polska are intended solely for laboratory and scientific research, and not for use in humans. Regulations regarding the possession, import and use of peptides vary by country and region.